DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ℹ️ Observational Association Only Evidence
Researchers used commercial and Medicaid claims from 1998 through 2023 to examine invasive pneumococcal disease among US children younger than 18 years. Incidence declined across age, insurance, and risk groups following pneumococcal conjugate vaccine introduction. However, children with chronic medical or immunocompromising conditions retained substantially higher rates than children without these conditions, with the largest relative disparities among older children. Claims-based case identification and unavailable vaccination and serotype data limit causal interpretation.
Clinical Considerations
- Commercially insured children with chronic conditions had 3.1 to 8.6 times higher incidence than children without identified risk conditions.
- Immunocompromised commercially insured children had 19.1 to 74.5 times higher incidence, with similar patterns in Medicaid data.
- Across the full study, immunocompromised children had approximately 34 to 39 times higher incidence than children without risk conditions.
- Absolute incidence was highest among children younger than 2 years, while relative disparities were greater among children aged 2 to 17 years.
- Rates reached their lowest levels during 2020 and 2021, then partially rebounded during the 2022–2023 post-COVID period.
- Claims lacked vaccination histories, pneumococcal serotypes, laboratory confirmation, and uninsured children, limiting attribution and national generalizability.
Practice Applications
- Review pneumococcal immunization status when children develop chronic medical or immunocompromising conditions.
- Recognize that older high-risk children retained pronounced relative disease disparities despite lower population-level incidence.
- Evaluate opportunities to improve uptake of currently recommended risk-based and catch-up vaccination.
- Interpret the widening rate ratios cautiously because vaccination coverage and infecting serotypes were unavailable.
- Monitor surveillance and immunization guidance as higher-valency vaccines alter residual pneumococcal disease patterns.
